Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Posted By Global Banking and Finance Review

Posted on January 21, 2025

Swiss biopharma firm BioVersys plans IPO in first quarter

ZURICH (Reuters) - Swiss biopharma company BioVersys said on Tuesday it plans to list on the Swiss stock exchange in the first quarter with an initial public offering that aims to raise around 80 million Swiss francs ($88 million).

The Basel-based company, whose existing shareholders include Britain's GSK, is focused on research and development of antibacterial products.

Proceeds from the IPO will be used to advance the firm's BV100 drug through phase 3 testing, with the goal of filing with major regulatory agencies at the end of 2027, and to help finance the firm from 2025 into 2028, BioVersys said.

Proceeds are also expected to support phase 2 development of BioVersys' alpibectir drug for treating tuberculosis.

The IPO is supported by GSK and other shareholders including the AMR Action Fund, BioVersys said in a statement.

($1 = 0.9082 Swiss francs)

(Reporting by Oliver Hirt; Writing by Dave Graham; Editing by Kirsti Knolle)

Recommended for you

  • UK's Serica Energy forecasts higher production in 2025

  • Sweden seeks to raise property tax on wind farms

  • Prince Harry's court battle with Murdoch papers begins